ICR Hosts Plus Therapeutics CEO Marc Hedrick on the Welcome to the Arena Podcast
06/28/2023 - 03:28 PM
NEW YORK --(BUSINESS WIRE)--
ICR , a leading strategic communications and advisory firm, is pleased to announce that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, recently appeared on Episode 81 of ICR’s “Welcome to the Arena” podcast.
Welcome to the Arena is hosted by Tom Ryan, Co-Founder & CEO of ICR. Tom spoke with Marc about the cutting-edge treatments at Plus Therapeutics, why they're different from traditional radiotherapy, and more.
The Welcome to the Arena podcast has featured discussions with CEOs, CFOs, financial analysts, members of the media, investment bankers, private equity executives and others who influence and create value for public and private-equity backed companies. The podcast made its debut in August 2021, airing episodes roughly every two weeks, and is available on Apple Podcasts Spotify Google Podcasts anywhere else
About ICR
Established in 1998, ICR partners with its clients to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. The firm’s highly-differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to approximately 1,000 clients across more than 20 industry groups. ICR’s healthcare practice operates under the Westwicke brand (www.westwicke.com ). Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America , maintaining offices in New York , Norwalk, Boston , Baltimore and Beijing . Learn more at www.icrinc.com . Follow us on Twitter at @ICRPR .
View source version on businesswire.com: https://www.businesswire.com/news/home/20230628959342/en/
Brian Ruby, ICR, 203-682-8268, brian.ruby@icrinc.com
Source: ICR
PSTV Rankings
N/A Ranked by Stock Gains
PSTV Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Austin
About PSTV
plus therapeutics, inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. its lead product candidate is doceplus, a protein-stabilized pegylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. the company is also involved in developing doxoplus, a generic pegylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and kaposi's sarcoma. it has a license agreement with nanotx, corp. to develop and commercialize nanotx's glioblastoma treatment. the company was formerly known as cytori therapeutics, inc. and changed its name to plus therapeutics, inc. in july 2019. plus therapeutics, inc. was founded in 1996 and is headquartered in austin, texas.
